Clinical Trial

Altered Neural Pain Empathic Reactivity in NSSI Adolescents

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 11, 2024 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
Nonsuicidal self-injury (NSSI) is defined as direct, deliberate bodily harm without suicidal intention. In recent years, growing evidence suggests that NSSI has become a worldwide public health issue. People with NSSI behaviors, especially adolescents, commonly exhibit emotion-related and interpersonal problems. Pain empathy represents an essential basal domain of socio-emotional processing and refers to the ability to empathize, connect and share with others' pain. However, altered empathic processing has not been systematically examined in adolescents with NSSI. To this end, the current functional magnetic resonance imaging (fMRI) study will recruit one group of NSSI adolescents (n=40) and one healthy control (HC) group (n=40), to compare their neural activity regarding pain empathy processing, which is measured by blood oxygenation level-dependent (BOLD) fMRI. The investigators included conditions of physical pain empathy (stimuli depicting noxious stimulation to the limbs) and affective pain empathy (stimuli depicting faces expressing pain) as well as corresponding control stimuli. The investigators hypothesize that compared to HC, NSSI adolescents show increased empathic reactivity to physical pain stimuli in salience and arousal related brain regions but decreased empathic reactivity to affective pain empathic stimuli.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-07-20; most recent amendment 2024-04-09.
Status change: Not Yet Recruiting → Recruiting 2024-04-09
Trial Details
NCT Number NCT05968313
Lead Sponsor University of Electronic Science and Technology of China
Conditions Nonsuicidal Self Injury, Pain Empathy
Enrollment 80 participants
Start Date 2023-12-06
Primary Completion 2026-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2024-04-11